Evidence map›Paper›PMID 27429184›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2016

Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action.

Kenneth H Mayer, Beatriz Grinsztejn, Wafaa M El-Sadr

Open access · hybridAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Self-Testing as a Hope to Reduce HIV in Transgender Women-Literature Review.International journal of environmental research and public health · 2022
    Review
  11. Article
  12. Review
  13. Article
  14. Evaluating Locally Developed Interventions to Promote PrEP Among Racially/Ethnically Diverse Transgender Women in the United States: A Unique CDC Initiative.AIDS education and prevention : official publication of the International Society for AIDS Education · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Kenneth H Mayer*Fenway Health/Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; †Fundação Oswaldo Cruz- FIOCRUZ, Rio de Janeiro, Brazil; and ‡ICAP at Columbia University Mailman School of Public Health, New York City, NY.
Beatriz Grinsztejn
Wafaa M El-Sadr
Beth Israel Deaconess Medical Center · USFundação Oswaldo Cruz · BR

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
Clinical Trial Unit for HIV Prevention and Microbicide ResearchUM1AI069480 · NIAID · FENWAY COMMUNITY HEALTH CENTER · PI MAYER, KENNETH H · 2012 to 2014
$2.3M
NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069476NIAID NIH HHS UM1 AI069480
6 · The paper itself

Abstract

Transgender people have been disproportionally affected by HIV, particularly transgender women. Their increased vulnerability to HIV is due to multiple issues, including biological (eg, increased efficiency of HIV transmission through receptive anal sex), epidemiological (eg, increased likelihood of having HIV-infected partners), structural (eg, social stigma limiting employment options), and individual factors (eg, internalized stigma leading to depression and substance use and risk-taking behaviors). There have been limited culturally appropriate HIV prevention interventions for transgender people, with many key prevention studies (eg, the iPrEx PrEP study) enrolling transgender women in a study focusing on men who have sex with men. This has resulted in limited understanding of the optimal ways to decrease transgender people's risk for HIV acquisition. The current supplement of JAIDS is designed to review what is known about HIV prevention for transgender people and to highlight new insights and best practices. The study reviews recent epidemiologic data, the pharmacology of HIV prophylactic agents in individuals who may be using exogenous hormones, and several recent multi-component interventions designed to address the lived experience of transgender people. Additionally, the study reviews the work going on at the NIH to address transgender health in general and HIV prevention in specific, as well as two important papers related to clinical trial design issues and the ethical conduct of research in this frequently disenfranchised population. It is the hope of the HIV Prevention Trials Network (HPTN) that this supplement will promote new knowledge around transgender health and the requisite issues that need to be addressed in order to conduct optimal clinical trials. The ultimate hope is that the information distilled in this supplement will inform investigators, clinicians, and public health officials in order to design further research to develop optimal prevention interventions for transgender people and to implement these interventions in ways that are culturally congruent and health promoting.

Indexed as

CondomsDelivery of Health Care, IntegratedDepressionFemaleHealth Services Needs and DemandHIV InfectionsHumansMaleMedication AdherencePre-Exposure ProphylaxisPrejudiceRisk-TakingSexual BehaviorSocial StigmaSubstance-Related DisordersTransgender Persons

Identifiers

PMID27429184
PMCPMC4969053
OpenAlexW2467090051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.